Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Dose and Frequency Finding Study of MOD-4023 in Adult Growth Hormone Deficiency
2010-019374-32Phase 2Completed
- Sponsor
- OPKO Biologics
- Start
- May 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of somatrogon in growth hormone deficiency (GHD), sponsored by OPKO Biologics. Primary endpoints: Mean time interval of IGF-I, Safety and tolerability and 1 more. Started May 2010; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2010-019374-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019374-32.